OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Summary
This lecture will describe the origin of the production of recombinant bioconjugate vaccines and recent developments in the technology
(for recent review see pubmed.ncbi.nlm.nih.gov/40733680)
I will describe the development of bioconjugation for the low-cost production of glycoconjugate vaccines in three areas; (i) against pathogens where no current vaccine exists (eg Group A Streptococcus), (ii) improving existing glycoconjugate vaccines (eg pneumococcal vaccine), and (iii) affordable glycoconjugate vaccines for the veterinary market (eg poultry). I will speculate on the production of low-cost bioconjugate vaccines in Low- and Middle-income countries including Campylobacter, S. pneumoniae and Group A Streptococcus
Bio
Brendan Wren moved to the LSHTM from St Bartholomew’s Hospital, London in 1999. He is currently Co-Director of the LSHTM Vaccine Centre and Co-Director of GlycoCell, a consortium for the efficient expression of glycan products in bacterial cells for improved vaccines. He has authored over 450 scientific peer-reviewed publications.
Current research focuses on glycosylation in bacterial pathogens and developing a “glycotoolbox” for glycoengineering. The major application of this technology is the construction and production of affordable recombinant glycoconjugate vaccines.
